Teladoc Health, the telehealth company that saw a surge in demand during the pandemic, reported second-quarter results that disappointed investors on both revenue and forward guidance. The stock fell more than 19% in Thursday's premarket trading after the company posted a wider-than-expected loss and trimmed its 2026 sales forecast.
Q2 results: revenue miss and wider loss
For the quarter ended June 30, Teladoc reported a net loss of $0.21 per diluted share, compared with a loss of $0.19 per share a year earlier. That was slightly better than the $0.25 loss analysts had expected, according to FactSet. But the bigger concern was revenue: sales dropped to $606.9 million from $631.9 million in the same period last year, falling short of the $615.4 million consensus estimate.
The revenue decline reflects ongoing challenges in Teladoc's core telehealth business, which has struggled to maintain the growth it saw during the height of the COVID-19 pandemic. The company's BetterHelp mental health platform, which had been a key growth driver, has also faced headwinds as competition intensifies and consumer spending shifts.
Lower 2026 outlook adds to investor concerns
Teladoc also provided a weaker-than-expected outlook for the third quarter and trimmed its 2026 revenue range. The company now expects third-quarter revenue of $569 million to $609 million, with a net loss of $0.30 to $0.20 per share. For 2026, it lowered its sales forecast to a range of $2.36 billion to $2.45 billion, down from its previous guidance.
This downward revision suggests that Teladoc's management sees a slower recovery in demand for its services than previously anticipated. The company has been investing in new products and partnerships to diversify its revenue streams, but the payoff appears to be taking longer than expected.
Other companies have also faced similar pressures. For instance, Wacker Chemie cut its sales outlook recently, though it lifted its profit target. In contrast, Teladoc's outlook revision is purely negative, with no offsetting profit improvement.
What it means for investors
For everyday investors, Teladoc's results highlight the risks of investing in companies that experienced a pandemic-era boom. The stock, which once traded at over $300 per share, has fallen sharply as growth normalized. The latest earnings miss and guidance cut suggest that the path to sustained profitability remains uncertain.
Investors should note that Teladoc is still losing money, and the company's ability to turn a profit depends on its ability to grow revenue while controlling costs. The lowered 2026 outlook indicates that management expects a longer runway to achieve its goals. This could mean further volatility in the stock price as the market adjusts to the new reality.
It's also worth watching how Teladoc's competitors are faring. The telehealth space has become increasingly crowded, with traditional healthcare providers and tech companies entering the market. Teladoc's ability to differentiate itself and maintain market share will be critical.
For context, other companies have also faced revenue headwinds recently. SES shares slid 11% after a revenue miss, showing that market reactions can be severe when expectations are not met. Similarly, Avolta's first-half sales growth was tempered by geopolitical issues, underscoring how external factors can impact results.
Looking ahead
Teladoc's next catalyst will likely be its third-quarter earnings report, due in late October. Investors will be watching closely to see if the company can stabilize revenue and narrow its losses. Any signs of improvement in the BetterHelp business or new contract wins could provide a boost to the stock.
In the meantime, the lowered 2026 outlook serves as a reminder that Teladoc's recovery is a long-term story, not a quick turnaround. For those holding the stock, patience will be key. For those considering an investment, it may be wise to wait for clearer signs of a growth inflection before jumping in.
As always, diversification is important. No single stock should dominate a portfolio, especially one with the kind of uncertainty Teladoc currently faces. The company's performance will depend on execution, competition, and broader economic trends, all of which are difficult to predict.
